company background image
GILD

Gilead Sciences NasdaqGS:GILD Stock Report

Last Price

US$62.00

Market Cap

US$77.8b

7D

4.1%

1Y

-10.5%

Updated

09 Aug, 2022

Data

Company Financials +
GILD fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends4/6

GILD Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$62.00
52 Week HighUS$74.12
52 Week LowUS$57.17
Beta0.35
1 Month Change-1.34%
3 Month Change2.38%
1 Year Change-10.46%
3 Year Change-3.58%
5 Year Change-15.21%
Change since IPO9,697.54%

Recent News & Updates

Aug 01

Gilead Q2 earnings to focus on slowing remdesivir sales

Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, after market close. The consensus EPS Estimate is $1.52 (-18.7% Y/Y) and the consensus Revenue Estimate is $5.87B (-5.6% Y/Y). Over the last 2 years, GILD has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 5 upward revisions and 6 downward. Revenue estimates have seen 5 upward revisions and 4 downward.  Last quarter, net income plummeted 99% to just $12M compared to the prior-year period driven by a one-time in-process research and development impairment charge of $2.7B. But, the biotech beat on both the top and bottom lines. Revenue rose 2.6% Y/Y to ~$6.6B. Sales of its COVID-19 treatment Veklury (remdesivir) rose 5% to ~1.5B. The company revised its full-year EPS to $3.00-$3.50 from $4.70-$5.20 previously. Wall Street estimates the company to earn $6.58. In July, Gilead signed deal with EU to deliver COVID-19 therapy, under which the countries can purchase up to ~2.3M vials of Veklury. It also received full approval for the drug. Investors will also be looking out for the performance of Gilead's other medicines such as HIV drug Biktarvy and oncology therapies Trodelvy and Yescarta.

Shareholder Returns

GILDUS BiotechsUS Market
7D4.1%6.3%0.3%
1Y-10.5%-25.9%-13.5%

Return vs Industry: GILD exceeded the US Biotechs industry which returned -25.9% over the past year.

Return vs Market: GILD exceeded the US Market which returned -13% over the past year.

Price Volatility

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement3.1%
Biotechs Industry Average Movement12.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: GILD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: GILD's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198714,400Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD fundamental statistics
Market CapUS$77.77b
Earnings (TTM)US$4.14b
Revenue (TTM)US$27.52b

18.8x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GILD income statement (TTM)
RevenueUS$27.52b
Cost of RevenueUS$5.64b
Gross ProfitUS$21.87b
Other ExpensesUS$17.74b
EarningsUS$4.14b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)3.30
Gross Margin79.50%
Net Profit Margin15.04%
Debt/Equity Ratio0.0%

How did GILD perform over the long term?

See historical performance and comparison

Dividends

4.7%

Current Dividend Yield

87%

Payout Ratio

Does GILD pay a reliable dividends?

See GILD dividend history and benchmarks
When do you need to buy GILD by to receive an upcoming dividend?
Gilead Sciences dividend dates
Ex Dividend DateSep 14 2022
Dividend Pay DateSep 29 2022
Days until Ex dividend35 days
Days until Dividend pay date50 days

Does GILD pay a reliable dividends?

See GILD dividend history and benchmarks